AAPS PharmSciTech

, Volume 8, Issue 3, pp E195–E202 | Cite as

Compressed matrix core tablet as a quick/slow dual-component delivery system containing ibuprofen

  • Carla Martins Lopes
  • José M. Sousa Lobo
  • João F. Pinto
  • Paulo C. Costa
Article

Abstract

The purpose of the present research was to produce a quick/slow biphasic delivery system for ibuprofen. A dual-component tablet made of a sustained release tableted core and an immediate release tableted coat was prepared by direct compression. Both the core and the coat contained a model drug (ibuprofen). The sustained release effect was achieved with a polymer (hydroxypropyl methylcellulose [HPMC] or ethylcellulose) to modulate the release of the drug. The in vitro drug release profile from these tablets showed the desired biphasic release behavior: the ibuprofen contained in the fast releasing component was dissolved within 2 minutes, whereas the drug in the core tablet was released at different times (⊂16 or >24 hours), depending on the composition of the matrix tablet. Based on the release kinetic parameters calculated, it can be concluded that the HPMC core was suitable for providing a constant and controlled release (zero order) for a long period of time.

Keywords

Biphasic delivery system dual-component tablet 

References

  1. 1.
    Maggi L, Machiste EO, Torre ML, Conte U. Formulation of biphasic release tablets containing slightly soluble drugs.Eur J Pharm Biopharm. 1999;48:37–42.CrossRefGoogle Scholar
  2. 2.
    Colombo P, Conte U, Gazzaniga A, et al. Drug release modulation by physical restrictions of matrix swelling.Int J Pharm. 1990;63:43–48.CrossRefGoogle Scholar
  3. 3.
    Qiu Y, Chidambaram N, Flood K. Design and evaluation of layered diffusional matrices for zero-order sustained release.J Control Release. 1998;52:123–130.CrossRefGoogle Scholar
  4. 4.
    Chidambaram N, Porter W, Flood K, Qui Y. Formulation and characterization of new layered diffusional matrices for zero-order sustained release.J Control Release 1998;52:149–158.CrossRefGoogle Scholar
  5. 5.
    Conte U, Maggi L. A flexible technology for the linear, pulsative and delayed release drugs, allowing for easy accommodation of difficult in vitro targets.J Control Release 2000;64:263–268.CrossRefGoogle Scholar
  6. 6.
    Uekama K, Matsubara K, Abe K, Horiuchi Y, Hirayamma F, Suzuki N. Design and in vitro evaluation of slow-release dosage form of piretanide: utility of beta-cyclodextrin: cellulose derivative combination as a modified-release drug carrier.J Pharm Sci. 1990;79:244–248.CrossRefGoogle Scholar
  7. 7.
    Li Y, Zhu J. Modulation of combined-release behaviours from a novel “tablets-in-capsule system.”J Control Release 2004;95:381–389.CrossRefGoogle Scholar
  8. 8.
    De Brabander C, Vervaet C, Görtz JP, Remon JP, Berlo JA. Bioavailability of ibuprofen from matrix mini-tablets based on a mixture of starch and microcrystallien wax.Int J Pharm. 2000;208:81–86.CrossRefGoogle Scholar
  9. 9.
    Colombo P, Bettini R, Santi P, Peppas NA. Swellable matrices for controlled drug delivery: gel-layer behavior, mechanisms and optimal performance.Pharm Sci Technol Today. 2000;3:198–204.CrossRefGoogle Scholar
  10. 10.
    Kiil S, Dam-Johansen K. Controlled drug delivery from swellable hydroxypropylmethylcellulose matrices: model-based analysis of observed radial front movements.J Control Release. 2003;90:1–21.CrossRefGoogle Scholar
  11. 11.
    Fell JT, Newton JM. The tensile strength of lactose tablets.J Pharm Pharmacol. 1968;20:657–659.Google Scholar
  12. 12.
    Morre JW, Flanner HH. Mathematical comparison of dissolution profiles.Pharm Technol. 1996;20:64–74.Google Scholar
  13. 13.
    CDER. Center for Drug Evaluation and Research, Guidance for Industry, Dissolution Testing of Immediate Release Solid Oral Dosage, 1997. Available at:http://www.fda.gov/cder/Guidance/1713bpl.pdf. Accessed: September 19, 2006.Google Scholar
  14. 14.
    EMEA. European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, Note for Guidance on Quality of Modified Release Products: (A) Oral Dosage Forms; (B) Transdermal Dosage Forms; Section I (Quality), CPMP/QWP/604/96 (1999). Available at: http://www.emea.eu.int/pdfs/human/qwp/060496en.pdf. Accessed: September 19, 2006.Google Scholar
  15. 15.
    Costa P, Sousa Lobo JM. Modelling and comparison of dissolution profiles.Eur J Pharm Sci. 2001;13:123–133.CrossRefGoogle Scholar
  16. 16.
    Ritger PL, Peppas NA. A simple equation for description of solute release. I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs.J Control Release. 1987;5:23–36.CrossRefGoogle Scholar
  17. 17.
    Donbrow M, Samuelov Y. Zero order drug delivery from double-layered porous films: release rate profiles from ethylcellulose, hydroxypropylcellulose and polyethylene glycol mixtures.J Pharm Pharmacol. 1980;32:463–470.Google Scholar
  18. 18.
    Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension.J Pharm Sci. 1961;50:874–875.CrossRefGoogle Scholar
  19. 19.
    Higuchi T. Mechanism of sustained-action medication: theoretical analysis of rate of release of soild drugs dispersed in solid matrices.J Pharm Sci. 1963;52:1145–1149.CrossRefGoogle Scholar
  20. 20.
    Korsmeyer RW, Gurny R, Doelker EM, Buri P, Peppas NA. Mechanism of solute release from porous hydrophilic polymers.Int J Pharm. 1983;15:25–35.CrossRefGoogle Scholar
  21. 21.
    Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers.Pharm Acta Helv. 1985;60:110–111.Google Scholar
  22. 22.
    Jacques CHM, Hopfenberg HB, Stannett V. Super case II transport of organic vapors in glassy polymers. In: Hopfenberger HB, ed.Permeability of Plastic Films and Coatings to Gases, Vapors, and Liquids, New York, NY: Plenum Press; 1974:73–86.Google Scholar
  23. 23.
    Waterman KC, Fergione MB. Press-coating of immediate release powders onto coated controlled release tablets with adhesives.J Control Release. 2003;89:387–395.CrossRefGoogle Scholar
  24. 24.
    Johansson B, Wikberg M, Ek R, Alderborn G. Compression behaviour and compactability of microcrystalline cellulose pellets in relationship to their pore structure and mechanical properties.Int. J. Pharm. 1995;117:57–73.CrossRefGoogle Scholar
  25. 25.
    Johansson B, Nicklasson F, Alderborn G. Effect of pellet size on degree of deformation and densification during compression and on compactability of microcrystalline cellulose pellets.Int J Pharm. 1998;163:35–48.CrossRefGoogle Scholar
  26. 26.
    Johansson B, Alderborn G. The effect of shape and porosity on the compression behaviour and tablet forming ability of granular materials formed from microcrystalline cellulose.Eur J Pharm Biopharm. 2001;52:347–357.CrossRefGoogle Scholar
  27. 27.
    Tunón A, Borjesson E, Frenning G, Alderborn G. Drug release from reservoir pellet compacted with some excipients of different physical properties.Eur J Pharm Sci. 2003;20:469–479.CrossRefGoogle Scholar
  28. 28.
    Lopes CM, Sousa Lobo JM, Pinto JF, Costa P. Compressed mini-tablets as a biphasic delivery system.Int J Pharm. 2006;323:93–100.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Carla Martins Lopes
    • 1
  • José M. Sousa Lobo
    • 1
  • João F. Pinto
    • 2
  • Paulo C. Costa
    • 1
  1. 1.Departmento de Tecnologia Farmacêutica, Faculdade de FarmáciaUniversidade do PortoPortoPortugal
  2. 2.Departmento de Tecnologia Farmacêutica, Faculdade de FarmáciaUniversidade de LisboaLisboaPortugal

Personalised recommendations